[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oncolytic-virus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oncolytic-virus":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100623594","phase-2-h101-plus-tace-for-rm-hnscc-100623594",false,"NCT07398664","H101 Plus TACE for r\u002Fm HNSCC","Recombinant Human Adenovirus 5 (H101) Combined With Transcatheter Arterial Chemoembolization (TACE) for the Treatment of Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma: A Single-Center, Prospective Study","Inclusion Criteria:\n\n1. Age between 18 and under 80 years old.\n2. Pathologically confirmed head and neck malignancies (including nasopharyngeal carcinoma, oral cavity cancer, oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, salivary gland cancer, nasal cavity and paranasal sinus cancer, etc.); patients who have failed at least two lines of standard treatment (including cetuximab and immuno check point inhibitors).\n3. Expected survival ≥3 months.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-2.\n5. Pre-treatment peripheral blood tests meet the following conditions: neutrophil count \\>2000\u002Fmm³, platelet count \\>100,000\u002Fmm³.\n6. Pre-treatment liver and kidney function meet the following: bilirubin \\\u003C1.5 mg\u002FdL, AST or ALT \\\u003C1.5 times the upper limit of normal, serum creatinine \\\u003C1.5 mg\u002FdL, creatinine clearance \\>60 mL\u002Fmin.\n7. Agreement to follow the trial treatment plan and visit schedule, voluntary participation, and written informed consent.\n\nExclusion Criteria:\n\n1. Expected survival less than 3 months.\n2. Positive pregnancy test for women of childbearing age.\n3. Concurrent diseases or conditions that affect the patient's ability to enroll normally or safety during the study period.\n4. Active psychiatric disorders or other psychological conditions that affect the patient's ability to sign the informed consent or understand the study.\n5. Severe coagulation abnormalities and\u002For active infection requiring intravenous anti-infective therapy.\n6. History of another malignancy within 5 years prior to screening, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or microscopic papillary thyroid carcinoma that have been treated with potential curative therapy.\n7. Severe cardiac arrhythmia or conduction abnormalities, and clinically uncontrolled hypertension (systolic blood pressure \\>150 mmHg and\u002For diastolic blood pressure \\>90 mmHg).\n8. Adverse reactions from prior anti-tumor treatments have not recovered to CTCAE version 5.0 Grade \\\u003C1 (except for toxicities judged by the investigator to pose no safety risk, such as alopecia, Grade 2 peripheral neuropathy, etc.).\n9. History of infectious diseases, such as positive HIV antibody test, active hepatitis B (defined as HBsAg positive during screening, with HBV-DNA levels above the upper limit of normal at the local laboratory), or hepatitis C (defined as positive HCV-Ab test during screening with positive HCV-RNA).\n10. Other conditions considered by the investigator to potentially affect patient compliance or make the patient unsuitable for participation in this study.","ALL","18 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r\u002Fm HNSCC patients.",[27,28,29],"Head and Neck Squamous Cell Carcinoma","Oncolytic Virus","TACE","NOT_YET_RECRUITING","2026-02-07",{"date":33,"type":34},"2026-02-10","ACTUAL",{"date":36,"type":21},"2026-02-15",{"date":38,"type":21},"2028-02-15",{"name":40,"class":41},"West China Hospital","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":17,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100494401","phase-1-oncolytic-virus-ad-td-nsil12-for-progressive-pediatric-diffuse-intrinsic-pontine-glioma-100494401","NCT05717699","Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma","Inclusion Criteria:\n\n1. Informed consent of the parents or patient.\n2. After surgical resection, biopsy, chemotherapy, or radiation therapy, tumor progression must be confirmed by MRI scan.\n3. Biopsy is performed prior to injection of Ad-TD-nsIL12 to confirm DIPG (frozen section-based).\n4. Pre-enrollment patients LPS (patients aged ≥1 and \\\u003C16 years) and KPS (patients aged ≥16 years) ≥ 50.\n5. Patient must be, in the investigator opinion, able to comply with all the protocol procedures.\n6. Age 1-18 years.\n7. A negative pregnancy test in fertile women (women are considered of childbearing potential (WOCBP) after menarche, unless permanently infertile, including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).\n8. Lesion considered by the investigator to be accessible for stereotactic biopsy.\n\nExclusion Criteria:\n\n1. Serious infections or intercurrent conditions, including but not limited to severe renal failure, liver failure, heart failure, or bone marrow failure, which are not permitted for inclusion according to the investigator's criteria. Patients must be afebrile (\\\u003C38℃) at the time of viral therapy.\n2. Other investigational medications within 30 days prior to viral treatment.\n3. Participants with immunodeficiency, autoimmune disease, or active hepatitis.\n4. Any medical or psychological condition that might interfere with the patient's ability to participate if older than 16 years or parents ability when younger than 16, or give informed consent or would compromise the patient's ability to tolerate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism.\n5. Tumor with multiple location.\n6. Pregnant or breast-feeding females.\n7. Severe bone marrow hypoplasia.\n8. Transaminases (aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT)) or total bilirubin \\> 3 times the upper limit of normal.\n9. Neutrophils \\\u003C 1x10\\^9\u002FL.\n10. Platelets ≤ 100x10\\^9\u002FL.\n11. Hemoglobin \\\u003C 9g\u002Fdl.\n12. Patients with Li-Fraumini syndrome or a known germline defect in the retinoblastoma gene or its associated pathways.\n13. Administer any type of vaccine within 30 days prior to Ad-TD-nsIL12 administration.\n14. Blood transfusions or drugs (such as G-CSF) within 28 days before viral treatment to treat pancytopenia or other hematological disorders.","1 Year",{"count":50,"type":21},18,[52],"PHASE1","This is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in progressive DIPG patients (NCI-CTCAE V5.0).",[28,55,56],"Diffuse Intrinsic Pontine Glioma","Adverse Drug Event","RECRUITING","2024-02-25",{"date":60,"type":34},"2024-02-28",{"date":62,"type":34},"2023-01-04",{"date":64,"type":21},"2028-01-04",{"name":66,"class":41},"Capital Medical University",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":17,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":81,"locationsCount":67},"100494402","phase-1-oncolytic-virus-ad-td-nsil12-for-primary-pediatric-diffuse-intrinsic-pontine-glioma-100494402","NCT05717712","Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma","Inclusion Criteria:\n\n1. Informed consent of the parents or patient.\n2. Patient must be, in the investigator opinion, able to comply with all the protocol procedures.\n3. Age 1-18 years.\n4. A negative pregnancy test in fertile women (women are considered of childbearing potential (WOCBP) after menarche, unless permanently infertile, including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).\n5. Patient newly diagnosed of DIPG in MRI.\n6. Pre-enrollment patients LPS (patients aged ≥1 and \\\u003C16 years) and KPS (patients aged ≥16 years) ≥ 50.\n7. Lesion considered by the investigator to be accessible for stereotactic biopsy. The location of the lesion allows injection without virus entering the ventricular system.\n8. No previous treatment for DIPG.\n\nExclusion Criteria:\n\n1. Serious infections or intercurrent conditions, including but not limited to severe renal failure, liver failure, heart failure, or bone marrow failure, which are not permitted for inclusion according to the investigator's criteria. Patients must be afebrile at baseline (\\\u003C38℃).\n2. Other investigational medications within 30 days prior to viral treatment.\n3. Participants with immunodeficiency, autoimmune disease, or active hepatitis.\n4. Any medical or psychological condition that might interfere with the patient's ability to participate if older than 16 years or parents ability when younger than 16, or give informed consent or would compromise the patient's ability to tolerate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism.\n5. Tumor with multiple location.\n6. Pregnant or breast-feeding females.\n7. Severe bone marrow hypoplasia.\n8. Transaminases (aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT)) or total bilirubin \\> 3 times the upper limit of normal.\n9. Neutrophils \\\u003C 1x10\\^9\u002FL.\n10. Platelets ≤ 100x10\\^9\u002FL.\n11. Hemoglobin \\\u003C 9 g\u002Fdl.\n12. Patients with Li-Fraumini syndrome or a known germline defect in the retinoblastoma gene or its associated pathways.\n13. Administer any type of vaccine within 30 days prior to Ad-TD-nsIL12 administration.\n14. Blood transfusions or drugs (such as G-CSF) within 28 days before baseline to treat pancytopenia or other blood disorders.",{"count":50,"type":21},[52],"This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients (NCI-CTCAE V5.0).",[28,55,56],{"date":60,"type":34},{"date":62,"type":34},{"date":64,"type":21},{"name":66,"class":41}]